
DGX AI Price Prediction
Track DGX's AI-powered predictions, market trends, and investment insights.
You don't hold DGX in your mock portfolio yet.
Track DGX's AI-powered predictions, market trends, and investment insights.
You don't hold DGX in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedWith EPS of 9.05 and a PE ratio of 22.52, Quest Diagnostics appears solidly profitable and valued at a modest premium to a typical mature healthcare services company. The valuation suggests investors expect steady, not explosive, earnings growth. In the absence of detailed revenue and margin history in the prompt, the data points provided indicate a stable, cash-generative business rather than a high-growth story.
The stock trading at $203.78, about 8.4% higher over the last month and above its 200‑day moving average of $188.84, signals positive price momentum. Trading above the 200‑day average typically indicates an established uptrend rather than a short‑term bounce. Without signs of extreme overbought conditions provided, the recent move looks like constructive strength rather than a blow‑off top.
Alternative data for Quest Diagnostics show encouraging signs of operational activity and brand engagement. Web traffic at over 15.2 million monthly visitors and a 100% month‑over‑month increase in job openings point to robust demand and potential expansion. Social media followings are broadly stable to slightly rising across most platforms, indicating steady brand presence rather than deterioration.
Quest Diagnostics shows a combination of solid profitability, constructive valuation, and clearly positive technical and alternative data signals. The stock’s move above its 200‑day moving average, coupled with strong hiring and high web traffic, suggests the market is correctly anticipating steady operational strength. Overall, the balance of evidence points to a bullish outlook, albeit driven more by durable, moderate growth than by aggressive upside.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Quest Diagnostics (DGX) is currently trading at $194.90 on the NYSE, reflecting a modest single-day decline of 0.7% against a market cap of $21.6 billion. Volume sits at 623,162 shares, suggesting measured but active participation. As one of the largest diagnostic information services providers in the U.S., DGX operates across routine and advanced clinical testing, anatomic pathology, and employer health services under multiple brands including AmeriPath and ExamOne. The stock's current price level positions it as a mid-large cap healthcare play in a sector defined by steady demand and incremental volume growth.
TrendEdge's AI model assigns DGX a score of 6 out of 10 — a neutral-to-moderate signal that reflects balanced fundamentals without a strong directional conviction in either direction. A score at this level typically indicates the stock is neither significantly undervalued nor under immediate technical pressure, but lacks the momentum or sentiment catalysts that would push it into high-conviction buy territory. With Reddit mentions at just 6 over the past seven days and no measurable positive or negative sentiment spike, retail interest remains subdued, which the AI factors in as a neutral social signal rather than a contrarian opportunity.
Looking ahead in 2026, key catalysts for DGX include reimbursement rate developments from payers, volume recovery in routine testing post any macro softness, and integration performance of recent acquisitions. Risks include pricing pressure from health plan negotiations, margin compression from labor costs, and competition from hospital-owned labs. Investors should monitor quarterly volume trends and any guidance revisions around test mix — particularly the shift toward higher-margin advanced and genomic testing — as these metrics will likely be the primary drivers of price movement.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
15,211,869
Twitter Followers
12,733
Instagram Followers
12,397
YouTube Subscribers
8,490
LinkedIn Followers
373,443
Job Postings
2,000
LinkedIn Employees
32,423
News Mentions
0
Key Metrics